Related Experiment Video

Updated: Apr 3, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.5K

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm

Cody Eslinger1, Mohamad Bassam Sonbol1, Ben George2

  • 1Department of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.

Drug Design, Development and Therapy
|April 2, 2026
PubMed

Insights

Pancreatic cancer (PDAC) treatments are advancing with new KRAS-targeted therapies. These inhibitors show promise in preclinical models and early trials, offering hope for this lethal disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options.
  • Activating KRAS mutations drive over 90% of PDAC cases, influencing tumor growth and treatment resistance.
  • KRAS was historically considered undruggable, hindering therapeutic progress.

Purpose of the Study:

  • To review the recent advances in targeting KRAS in pancreatic cancer.
  • To discuss the potential of novel KRAS-directed therapies and combination strategies.
  • To highlight the shift towards molecularly guided treatments for PDAC.

Main Methods:

  • Review of preclinical models and early-phase clinical trials of KRAS inhibitors.
  • Analysis of emerging combination strategies involving KRAS-targeted agents.
  • Exploration of novel therapeutic approaches like KRAS degradation and RNA-targeted therapies.

Main Results:

  • KRAS is now a druggable target with allele-specific and pan-RAS(ON) inhibitors.
  • These therapies demonstrate significant antitumor activity and tumor microenvironment modulation.
  • Evidence suggests delayed development of therapeutic resistance.

Conclusions:

  • Targeting KRAS represents a paradigm shift in PDAC treatment.
  • Combination strategies are crucial for enhancing treatment depth and durability.
  • Molecularly guided therapies offer a promising future for PDAC patients with unmet needs.
Keywords:
KRASchemotherapynext generation sequencingpancreatic cancertargeted therapy

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

910
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K